Solanezumab-话题@MedSci

#Solanezumab#

3篇内容 | 1075人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2118654, encodeId=c51a2118654b5, content=52名携带突变的参与者被分配接受<a href='/topic/show?id=013fe83352' target=_blank style='color:#2F92EE;'>#gantenerumab#</a>治疗，52名参与者接受<a href='/topic/show?id=536016532df' target=_blank style='color:#2F92EE;'>#Solanezumab#</a>治疗，另外40名参与者接受安慰剂治疗。两种药物都涉及其Aβ靶点，但与对照组相比，都没有显示出对认知能力的有益影响。<a href='/topic/show?id=e3009e77006' target=_blank style='color:#2F92EE;'>#阿尔兹海默症#</a>，太难了，又倒下两个, objectTitle=Nat Med：遗憾，Gantenerumab或Solanezumab对于显性遗传阿尔兹海默症无效, objectType=article, longId=213067, objectId=919921306ed9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/142214-forgetting.jpg, objectUrl=/article/show_article.do?id=919921306ed9, replyNumber=0, likeNumber=141, createdTime=2023-03-10, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=919921306ed9, moduleTitle=Nat Med：遗憾，Gantenerumab或Solanezumab对于显性遗传阿尔兹海默症无效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=919921306ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039462, encodeId=911920394625b, content=<a href='/topic/show?id=536016532df' target=_blank style='color:#2F92EE;'>#Solanezumab#</a>, objectTitle=Nat Med：遗憾，Gantenerumab或Solanezumab对于显性遗传阿尔兹海默症无效, objectType=article, longId=213067, objectId=919921306ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=919921306ed9, replyNumber=0, likeNumber=85, createdTime=2022-06-06, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=919921306ed9, moduleTitle=Nat Med：遗憾，Gantenerumab或Solanezumab对于显性遗传阿尔兹海默症无效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=919921306ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039461, encodeId=6c1720394618d, content=<a href='/topic/show?id=536016532df' target=_blank style='color:#2F92EE;'>#Solanezumab#</a>, objectTitle=NEJM：阿尔茨海默病新药Solanezumab III期临床试验失败, objectType=article, longId=30355, objectId=46a930355d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46a930355d0, replyNumber=0, likeNumber=75, createdTime=2015-01-18, rootId=0, userName=12498ef1m31(暂无昵称), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46a930355d0, moduleTitle=NEJM：阿尔茨海默病新药Solanezumab III期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46a930355d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Solanezumab

2020-05-29

showtest (审核中...)

前往app查看评论内容

52名携带突变的参与者被分配接受#gantenerumab#治疗，52名参与者接受#Solanezumab#治疗，另外40名参与者接受安慰剂治疗。两种药物都涉及其Aβ靶点，但与对照组相比，都没有显示出对认知能力的有益影响。#阿尔兹海默症#，太难了，又倒下两个

Nat Med：遗憾，Gantenerumab或Solanezumab对于显性遗传阿尔兹海默症无效

2023-03-10发表于上海

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#Solanezumab#

Nat Med：遗憾，Gantenerumab或Solanezumab对于显性遗传阿尔兹海默症无效

2022-06-06

12498ef1m31(暂无昵称) (审核中...)

前往app查看评论内容

#Solanezumab#

NEJM：阿尔茨海默病新药Solanezumab III期临床试验失败

2015-01-18

科室
- - 订阅+
  - 更多科室
工具
服务